These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23376866)

  • 1. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs.
    Darbà J; Kaskens L; Aranda P; Arango C; Bobes J; Carmena R; Rejas J
    Ann Clin Psychiatry; 2013 Feb; 25(1):17-26. PubMed ID: 23376866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
    Daumit GL; Goff DC; Meyer JM; Davis VG; Nasrallah HA; McEvoy JP; Rosenheck R; Davis SM; Hsiao JK; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Oct; 105(1-3):175-87. PubMed ID: 18775645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.
    Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2007 Feb; 90(1-3):162-73. PubMed ID: 17123783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
    Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
    J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics.
    Citrome L; Collins JM; Nordstrom BL; Rosen EJ; Baker R; Nadkarni A; Kalsekar I
    J Clin Psychiatry; 2013 Dec; 74(12):1199-206. PubMed ID: 24434088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
    Park T; Kuntz KM
    Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CATIE schizophrenia trial: results, impact, controversy.
    Manschreck TC; Boshes RA
    Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
    Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
    Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Stip E
    Expert Opin Drug Saf; 2012 Sep; 11(5):713-32. PubMed ID: 22913713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
    Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
    J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.